Summit Therapeutics (NASDAQ:SMMT) has seen its share price surge by 28.19 percent week-on-week, primarily driven by the positive results of an ongoing clinical trial for its bispecific antibody, ivonescimab.
In an updated report during the week, the listed biopharmaceutical firm said that its China-based partner, Akeso Inc., saw positive overall survival results from the randomized double-blind Phase 3 Harmoni-2 study evaluating ivonescimab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression.
It also reported a statistically significant improvement compared with pembrolizumab monotherapy, which could pave the way for a better treatment option for patients.
Final results from the trial are set to be presented at an upcoming medical conference.
Photo by Tima Miroshnichenko on Pexels
Chemo Combo for Biliary Tract Cancer
Aside from NSCLC, Akeso is also testing ivonescimab in other indications, including for advanced biliary tract cancer.
Late in August, Summit Therapeutics said that its partner reported positive topline results evaluating the antibody versus durvalumab as a first-line treatment, in combination with chemotherapy.
According to Akeso, the ivonescimab-based regimen achieved statistically significant and clinically meaningful superiority in the primary endpoint of overall survival (OS) compared to the durvalumab-based regimen. It also met the key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR).
Detailed results from this first readout, including safety and efficacy data, are expected to be presented at an upcoming medical congress and published in a peer-reviewed journal.
What It Means for Summit Therapeutics
The twin results could further strengthen the investment case for Summit Therapeutics, as ivonescimab continues to demonstrate encouraging efficacy across multiple cancer indications.
Additionally, it signified that ivonescimab holds the potential to treat other indications beyond lung cancer, giving it multiple opportunities to expand its addressable market and additional sources of revenue.
Despite the positive results, investors must still keep in mind that the drug remains in clinical development and has yet to be approved by any food and drug regulatory agency.
Positive results do not guarantee any regulatory approval or commercial success, which makes upcoming detailed trial data, regulatory findings, and additional clinical readouts serve as an important indication in determining whether the therapy candidate can ultimately translate the promising results into a commercially successful treatment.
Hedge Fund Conviction Weakens
Institutional investors appeared to have exercised caution for Summit Therapeutics in the second quarter of the year, as evidenced by the drop in their committed capital despite a higher number of hedge funds seeking exposure.
During the period, 39 hedge funds held positions in the company, up from 34 in the first quarter of the year.
However, their combined holdings declined by 6.6 percent to $824.6 million from $883 million quarter-on-quarter, signaling that they are likewise waiting for more concrete catalysts to help boost buying appetite.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
